# MediciNova

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medicinova

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.medicinova.com
- Total disclosed funding: $83M
- Latest round: Series C (Sep 3, 2004)
- Investors on record: 18

## About

Founded in 2000 and based in California, US, MediciNova, Inc. is a biopharmaceutical company that develops small-molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by President and CEO Yuichi Iwaki, M.D., Ph.D. In January 2021, MediciNova, Inc. raised USD 20 million in PIPE Funding led by new investor 3D Investment Partners.

MediciNova is a biopharmaceutical company that is developing novel therapeutics with a primary focus on neurology, respiratory, and liver diseases with unmet medical needs. The company portfolio products include therapeutics such as MN-001 for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF); MN-166 for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM); and MN-221 for Respiratory Diseases such as asthma.

## Funding rounds

- Series C, Sep 3, 2004, $44M — Essex Woodlands, CDIB Capital Group, Daiwa Corporate Investment, Nippon Venture Capital, University of Tokyo Edge Capital Partners, Mizuho Securities, New Business Investment Corporation, Black Diamond Capital, POSCO BioVentures, SMBC Nikko Capital Markets, Aqua RIMCO, Biovision Life Sciences Fund, JCE Hottinger & Co
- Series B, Jun 1, 2004, $29M — Essex Woodlands, Whiz Partners, JAFCO Group, bhp, MORI TRUST CO., LTD.
- Series A, Sep 1, 2000, $10M — MP Healthcare Venture Management

## Investors

- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series A
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series B, Series C
- Whiz Partners (https://capitalatlas.ai/funds/whiz-partners) — Series B
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series B
- bhp (https://capitalatlas.ai/funds/bhp) — Series B
- MORI TRUST CO., LTD. — Series B
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series C
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series C
- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series C
- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series C
- Mizuho Securities — Series C
- New Business Investment Corporation — Series C
- Black Diamond Capital (https://capitalatlas.ai/funds/black-diamond-capital) — Series C
- POSCO BioVentures (https://capitalatlas.ai/funds/posco-bioventures) — Series C
- SMBC Nikko Capital Markets — Series C
- Aqua RIMCO (https://capitalatlas.ai/funds/aqua-rimco) — Series C
- Biovision Life Sciences Fund — Series C
- JCE Hottinger & Co — Series C